MedTrace Logo

Evaluation of Blood TMB for the Efficacy of Atezolizumab [BUDDY]

NCT04059887 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2023-02-08

No results posted yet for this study

Summary

This is single arm, prospective, multi-center, cohort study to evaluate blood TMB for improved efficacy of atezolizumab in locally advanced or metastatic NSCLC at the study enrollment who failed one or more prior lines of chemotherapy including at least 1 platinum-based.

Conditions

  • Lung Neoplasm Malignant

Interventions

DRUG

Atezolizumab Injection [Tecentriq]

Blood sampling will be performed before and after 3rd cycle of atezolizumab for evaluation of tumor mutation burden

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • Chonnam National University Hospital

    lead OTHER

Principal Investigators

  • In-Jae Oh, MD, PhD · Chonnam National Univeristy Hwasun Hospital

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-18
Primary Completion
2021-12-31
Completion
2022-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04059887 on ClinicalTrials.gov